Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Jiangsu Sinopep-Allsino Biopharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Jiangsu Sinopep-Allsino Biopharmaceutical has a total shareholder equity of CN¥2.4B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 46.6%. Its total assets and total liabilities are CN¥4.0B and CN¥1.6B respectively. Jiangsu Sinopep-Allsino Biopharmaceutical's EBIT is CN¥395.6M making its interest coverage ratio 25.6. It has cash and short-term investments of CN¥740.2M.
Anahtar bilgiler
46.6%
Borç/özkaynak oranı
CN¥1.13b
Borç
| Faiz karşılama oranı | 25.6x |
| Nakit | CN¥740.22m |
| Eşitlik | CN¥2.42b |
| Toplam yükümlülükler | CN¥1.59b |
| Toplam varlıklar | CN¥4.02b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?
Sep 26
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Jun 23Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 04There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump
Mar 04Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 688076's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥1.3B).
Uzun Vadeli Yükümlülükler: 688076's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥341.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 688076's net debt to equity ratio (16%) is considered satisfactory.
Borcun Azaltılması: 688076's debt to equity ratio has increased from 14.8% to 46.6% over the past 5 years.
Borç Kapsamı: 688076's debt is well covered by operating cash flow (33.4%).
Faiz Kapsamı: 688076's interest payments on its debt are well covered by EBIT (25.6x coverage).